These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 32077361

  • 1. Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasm.
    Palmieri R, Buckley SA, Othus M, Halpern AB, Percival MM, Scott BL, Hendrie PC, Becker PS, Oehler VG, Estey EH, Walter RB.
    Leuk Lymphoma; 2020 Jul; 61(7):1728-1731. PubMed ID: 32077361
    [No Abstract] [Full Text] [Related]

  • 2. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
    Zhang N, Li H, Wang D, Wang Z, Zhu JS, Chen K, Jiang H, Shao JB, Cai C.
    Clin Epigenetics; 2024 May 09; 16(1):63. PubMed ID: 38725010
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J, Lv TT, Zhou XF, Huang Y, Liu DD, Yuan GL.
    Medicine (Baltimore); 2018 Sep 09; 97(39):e12102. PubMed ID: 30278488
    [Abstract] [Full Text] [Related]

  • 4. Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
    Jin M, Hu Y, Wu W, Luo Y, Tan Y, Yu J, Jin A, Yang L, Huang H, Wei G.
    BMC Cancer; 2019 Mar 18; 19(1):242. PubMed ID: 30885156
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
    Ruan M, Liu LP, Zhang AL, Quan Qi B, Liu F, Liu TF, Liu XM, Chen XJ, Yang WY, Guo Y, Zhang L, Zou Y, Chen YM, Zhu XF.
    Cancer Med; 2021 Feb 18; 10(3):956-964. PubMed ID: 33491298
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A, Robak T, Pluta A, Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S, Giebel S, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Kiełbiński M, Zawilska K, Kłoczko J, Wrzesień-Kuś A, Polish Adult Leukemia Group.
    Eur J Haematol; 2008 Feb 18; 80(2):115-26. PubMed ID: 18076637
    [Abstract] [Full Text] [Related]

  • 9. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
    Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.
    Leukemia; 2017 Dec 18; 31(12):2560-2567. PubMed ID: 28555084
    [Abstract] [Full Text] [Related]

  • 10. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H, Wang L, Li C, Wuxiao Z, Shao R, Wang H, Lu Y.
    Oncologist; 2020 Nov 18; 25(11):e1663-e1670. PubMed ID: 32845551
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
    Mi RH, Chen L, Yang HP, Wang XJ, Guo SL, Shi L, Yin QS, Wei XD.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr 18; 29(2):333-338. PubMed ID: 33812396
    [Abstract] [Full Text] [Related]

  • 15. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
    Zhang J, Sun Y, Zhang X, Long B, Lu Y, Li X.
    Transplant Proc; 2018 Apr 18; 50(1):246-249. PubMed ID: 29407318
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
    Cao S, Tao Q, Wang J, Zhang Q, Dong Y.
    Medicine (Baltimore); 2023 Nov 03; 102(44):e34949. PubMed ID: 37933074
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.